The drug discovery pipeline for leishmaniasis and trypanosomiasis has been filling with novel chemical entities with known mechanisms of action. González et al. and Braillard et al. report a cytochrome bc1 complex inhibitor as another promising preclinical candidate for visceral leishmaniasis (VL) and, in combination with benznidazole, for chronic Chagas' disease (CCD).
Keywords: chronic Chagas’ disease; cytochrome b; drug combinations; visceral leishmaniasis.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.